NASDAQ: RNTXRein Therapeutics Inc Stock
$0.91-0.07 (-7.14%)
Updated Jul 13, 2026
RNTX Price
$0.91
Fair Value Price
$0.13
Market Cap
$77.58M
52 Week Low
$0.86
52 Week High
$2.18
P/E
-0.48x
P/B
6.69x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$50.21M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.27
Operating Cash Flow
-$17M
Beta
1.04
Next Earnings
Aug 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
RNTX Overview
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RNTX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important RNTX news, forecast changes, insider trades & much more!
RNTX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RNTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RNTX ($0.91) is overvalued by 617.84% relative to our estimate of its Fair Value price of $0.13 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
RNTX ($0.91) is not significantly undervalued (617.84%) relative to our estimate of its Fair Value price of $0.13 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
RNTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RNTX due diligence checks available for Premium users.
Valuation
RNTX fair value
Fair Value of RNTX stock based on Discounted Cash Flow (DCF)
Price
$0.91
Fair Value
$0.13
Overvalued by
620.21%
RNTX ($0.91) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RNTX ($0.91) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RNTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
RNTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.48x
Industry
17.69x
Market
12.5x
RNTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.69x
Industry
5.42x
RNTX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RNTX's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.8M
Profit Margin
0%
RNTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$26.3M
Liabilities
$14.7M
Debt to equity
1.27
RNTX's short-term liabilities ($13.64M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RNTX's short-term assets ($5.45M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RNTX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
RNTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.4M
Investing
$0.0
Financing
$4.7M
RNTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RNTX vs Biotech Stocks
Rein Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.